Zolgensma (Onasemnogene Abeparvovec)

Introduction

Zolgensma (Onasemnogene Abeparvovec) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

flowchart TD
    Zolgensma__Onasemnogene_Abepar["Zolgensma Onasemnogene Abeparvovec"]
    Zolgensma__Onasemnogene_Abepar["Onasemnogene"]
    Zolgensma__Onasemnogene_Abepar -->|"related to"| Zolgensma__Onasemnogene_Abepar
    style Zolgensma__Onasemnogene_Abepar fill:#81c784,stroke:#333,color:#000
    Zolgensma__Onasemnogene_Abepar["Abeparvovec"]
    Zolgensma__Onasemnogene_Abepar -->|"related to"| Zolgensma__Onasemnogene_Abepar
    style Zolgensma__Onasemnogene_Abepar fill:#81c784,stroke:#333,color:#000
    Zolgensma__Onasemnogene_Abepar["Introduction"]
    Zolgensma__Onasemnogene_Abepar -->|"related to"| Zolgensma__Onasemnogene_Abepar
    style Zolgensma__Onasemnogene_Abepar fill:#81c784,stroke:#333,color:#000
    style Zolgensma__Onasemnogene_Abepar fill:#4fc3f7,stroke:#333,color:#000

Zolgensma (generic name onasemnogene abeparvovec-xioi; development code AVXS-101) is a recombinant adeno-associated virus serotype 9 (AAV9)-based gene therapy developed by AveXis (now part of Novartis Gene Therapies) for the treatment of spinal-muscular-atrophy (SMA). It delivers a functional copy of the human smn1 gene to motor neuron cells, addressing the root genetic cause of SMA — loss-of-function mutations in the SMN1 gene that lead to insufficient levels of survival motor neuron (smn protein and progressive motor-neurons degeneration.^{1Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy, NEJM 20172017 · DOI 10.1056/NEJMoa1706198Open reference 2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference}

The U.S. Food and Drug Administration (FDA) originally approved Zolgensma in May 2019 for pediatric patients under 2 years of age with SMA, making it one of the first gene-therapy approved for a [neurodegenerative disease. In December 2025, the FDA expanded approval to include patients aged 2 to under 18 years via intrathecal administration, based on the pivotal STEER trial results.^{2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference} Zolgensma was initially priced at approximately $2.125 million for a single dose, making it one of the most expensive pharmaceutical products in history at launch. ^{3Identification and Characterization of a Spinal Muscular Atrophy-Determining Gene, Cell 19951995 · DOI 10.1016/0092-8674(95Open reference}

Mechanism of Action

Gene Replacement Strategy

spinal-muscular-atrophy is caused by homozygous deletions or mutations in the smn1 gene on chromosome 5q13, resulting in deficient production of the full-length SMN protein essential for motor-neurons survival and function. The severity of SMA is modulated by the copy number of a closely related gene, SMN2, which produces predominantly a truncated, unstable SMN protein due to alternative splicing of exon 7.^{3Identification and Characterization of a Spinal Muscular Atrophy-Determining Gene, Cell 19951995 · DOI 10.1016/0092-8674(95Open reference 4Rescue of the Spinal Muscular Atrophy phenotype in a mouse model by early postnatal delivery of SMN, Nature Biotechnology 20102010 · DOI 10.1038/nbt.1610Open reference}

Onasemnogene abeparvovec uses a non-replicating, self-complementary AAV9 vector to deliver a functional copy of the human SMN1 transgene under the control of a cytomegalovirus (CMV) enhancer/chicken β-actin hybrid promoter. Key features of the mechanism include: ^{5A Novel Function for SMN in Pre-mRNA Splicing, Cell 19981998 · DOI 10.1016/S0092-8674(00Open reference}

• AAV9 tropism: The AAV9 serotype was selected for its ability to cross the blood-brain-barrier after intravenous administration and efficiently transduce motor-neurons in the spinal cord, brainstem, and motor cortex

• Self-complementary genome: The vector contains a self-complementary DNA configuration that bypasses the rate-limiting step of second-strand synthesis, enabling rapid transgene expression

• Non-integrating: The AAV9 vector remains primarily as episomal DNA in the host cell nucleus, reducing the risk of insertional mutagenesis

• Persistent expression: Because motor-neurons are post-mitotic (non-dividing), the episomal transgene DNA is maintained long-term, providing durable SMN protein production^{4Rescue of the Spinal Muscular Atrophy phenotype in a mouse model by early postnatal delivery of SMN, Nature Biotechnology 20102010 · DOI 10.1038/nbt.1610Open reference}

Intracellular Pathway

Once the AAV9 capsid enters the motor neuron via receptor-mediated endocytosis (primarily through AAVR, the AAV receptor), it trafficks through the endosomal pathway to the nucleus. The self-complementary DNA genome is released and forms stable episomal concatemers. Transcription from the hybrid CMV/CBA promoter produces full-length SMN mRNA, which is translated into functional SMN protein. This protein restores the assembly of small nuclear ribonucleoproteins (snRNPs), which are essential for pre-mRNA splicing in motor neurons.^{5A Novel Function for SMN in Pre-mRNA Splicing, Cell 19981998 · DOI 10.1016/S0092-8674(00Open reference 6MDA Conference 2026, Long-Term Follow-Up of Onasemnogene Abeparvovec in SMA Type 12026Open reference}

Routes of Administration

• Intravenous (IV): One-time IV infusion at 1.1 × 10¹⁴ vector genomes per kilogram of body weight; approved for patients under 2 years of age. The IV route achieves systemic transduction including motor-neurons, dorsal root ganglia, and peripheral tissues

• Intrathecal (IT): Lumbar puncture delivery directly into the cerebrospinal fluid; approved for patients aged 2 to <18 years. The IT route achieves more targeted CNS transduction with a lower total vector dose and potentially reduced systemic exposure^{2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference}0

Clinical Trials

START Trial (Phase 1)

The first-in-human START trial (NCT02122952) enrolled 15 infants with SMA type 1 who received intravenous onasemnogene abeparvovec. The high-dose cohort (n=12) showed remarkable results: all 12 patients were alive and free of permanent ventilation at 20 months of age (compared to the 8% expected natural history), with 11 of 12 achieving head control and 9 of 12 able to sit independently. Two patients could walk independently — milestones never achieved in untreated SMA type 1.^{2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference}1 ^{2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference}2

Long-term follow-up through 7+ years has demonstrated durable SMN protein expression and sustained motor function, with no evidence of transgene expression decline, confirming the one-time treatment paradigm.^{2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference}3 ^{2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference}4

STR1VE Trials (Phase 3)

The pivotal STR1VE-US (NCT03306277) and STR1VE-EU (NCT03461289) trials enrolled symptomatic SMA type 1 infants. In STR1VE-US: ^{2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference}5

• 91% survival free of permanent ventilation at 14 months of age (vs. 25% historical control)

• 59% achieved sitting independently for ≥30 seconds

• Significant improvements in CHOP-INTEND motor function scores

These results confirmed the START findings and supported FDA approval for patients under 2 years.^{2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference}6 ^{2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference}7

STEER Trial (Phase 3, Intrathecal)

The STEER trial (NCT05089656) was a randomized, sham-controlled study evaluating intrathecal onasemnogene abeparvovec in 126 treatment-naïve patients aged 2 to <18 years with SMA type 2. At 52 weeks: ^{2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference}8

• Treated patients achieved a 2.39-point improvement on the Hammersmith Functional Motor Scale Expanded (HFMSE) vs. 0.51 points in the sham arm (p<0.001)

• Clinically meaningful motor function gains were observed across age groups

• Results supported the December 2025 expanded FDA approval^{2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference}9

STRENGTH Trial (Phase 3b, Treatment-Experienced)

The STRENGTH trial (NCT05386680) evaluated intrathecal onasemnogene abeparvovec in patients aged 2 to <18 years who had previously been treated with nusinersen (Spinraza) or risdiplam (Evrysdi). Results demonstrated a favorable safety profile consistent with treatment-naïve populations and suggested clinical benefit in patients switching from other SMA therapies.^{2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference}0 ^{2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference}1

Safety Profile

Hepatotoxicity

The most significant safety concern is hepatotoxicity, reported in approximately 34–43% of patients across clinical trials. The mechanism is believed to involve immune-mediated liver injury triggered by AAV9 capsid transduction of hepatocytes and subsequent T-cell recognition of viral capsid epitopes:

• Manifests primarily as elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST)

• Typically occurs 1–2 months post-infusion

• Managed with prophylactic and therapeutic systemic corticosteroids (prednisolone)

• A minimum 60-day corticosteroid taper is standard of care^{2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference}2

Thrombotic Microangiopathy (TMA)

Thrombotic microangiopathy has been identified as a rare but serious adverse event in the postmarketing setting:

• More prevalent in patients weighing ≥8.5 kg

• Requires monitoring of platelet counts, hemoglobin, and kidney function

• Can present with thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury^{2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference}3

Other Adverse Events

• Thrombocytopenia (21% of patients) — transient platelet decreases

• Cardiac events (18%) — primarily asymptomatic elevated troponin I levels

• Dorsal root ganglion (DRG) toxicity — observed in preclinical studies at high doses; sensory neuron degeneration monitored clinically

• Vomiting and pyrexia — common infusion-related reactions^{2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference}4

Comparison with Other SMA Therapies

Pharmacoeconomics and Access

Zolgensma’s initial list price of 2.125 million made it a landmark case in pharmaceutical pricing debates. Economic analyses have argued that the one-time cost may be offset by avoided lifetime treatment costs of chronic therapies (nusinersen costs approximately 750,000 in the first year and $375,000 annually thereafter) and by the substantial reduction in healthcare utilization for SMA patients.^{2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference}5

Novartis has implemented outcomes-based agreements with payers and a managed access program to improve global availability, particularly in countries where SMA newborn screening enables early detection and treatment.

Current Research and Future Directions

• Combination approaches: Investigation of Zolgensma with SMN2-enhancing therapies (nusinersen or risdiplam for maximum SMN protein restoration

• Next-generation vectors: Development of improved AAV capsids with enhanced CNS tropism and reduced immunogenicity

• Pre-symptomatic treatment: Expansion of newborn screening programs enables treatment before symptom onset, with early data suggesting near-normal motor development

• Extension to other motor neuron diseases: AAV-based gene therapy platforms are being explored for als and other neurodegenerative conditions^{2Novartis, Phase III data demonstrate meaningful efficacy of intrathecal onasemnogene abeparvovec, 20252025Open reference}6

See Also

• motor-neurons

• smn

• antisense-oligonucleotide-therapy

• gene-therapy

• nusinersen

• risdiplam

External Links

• ClinicalTrials.gov — Zolgensma studies

• FDA Label — Zolgensma

• Novartis — Zolgensma

• Cure SMA — Zolgensma

Background

The study of Zolgensma (Onasemnogene Abeparvovec) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• Allen Brain Atlas - Gene Expression - Search for gene expression data across brain regions

• Allen Brain Atlas - Cell Types - Explore neuronal cell type taxonomy

• Allen Brain Atlas - Aging, Dementia & TBI - Data on aging and traumatic brain injury